At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Ranibizumab +2 moredrug
Likely dose
Ranibizumab 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Occlusion Prevention for Trabeculectomy Procedures Using Combination Ranibizumab and Mitomycin C (MMC) During Surgery (OCTOPUS Study)
In Brief
A Phase 2 clinical trial evaluating Ranibizumab, Ranibizumab and MMC, and 1 other intervention for Glaucoma. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of the study is to study the safety of the combination of ranibizumab and MMC vs monotherapy MMC vs intravitreal ranibizumab injection in patients with glaucoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedApr 2008
Primary CompletionSep 2014
TodayJul 2026
First PostedApr 18, 2008
Enrollment StartApr 1, 2008
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 18.2 years ago
Interventions
Ranibizumabdrug
0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
Ranibizumab and MMCdrug
Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy
MMCdrug
MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.